Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Deepti Bala Kallam"'
Publikováno v:
Journal of Clinical Oncology. 37:94-94
94 Background: Bortezomib is a novel first-in-class proteasome inhibitor and received it’s FDA approval with twice weekly dosing on day 1, 4, 8 and 11 of a 21-day cycle with weekly complete blood count (CBC). However, subsequent studies have shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823ed313306ef502e22012d7fcd64a8a
https://doi.org/10.1200/jco.2019.37.27_suppl.94
https://doi.org/10.1200/jco.2019.37.27_suppl.94
